HIV encephalitis in a patient on antiretroviral therapy: a case report

2019 ◽  
Vol 30 (6) ◽  
pp. 617-619 ◽  
Author(s):  
Maria Hlebowicz ◽  
Miłosz Parczewski ◽  
Paweł Jakubowski
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Cerebrospinal Fluid ◽  
Case Report ◽  
Antiretroviral Therapy ◽  
Viral Escape ◽  
Resistance Testing ◽  
Hiv Encephalitis ◽  
Hiv Resistance ◽  
Immunodeficiency Virus

We present the case of a 52-year-old man with human immunodeficiency virus (HIV) encephalitis resulting from cerebrospinal fluid (CSF) viral escape, to illustrate therapeutic challenges in patients with emergent CSF genotypic HIV drug resistance. This case report highlights the usefulness of CSF HIV-resistance testing to guide antiretroviral therapy and treatment optimizing decisions.

scholarly journals Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance

2003 ◽  
Vol 37 (8) ◽  
pp. 1112-1118 ◽  
Author(s):  
A. K. Sethi ◽  
D. D. Celentano ◽  
S. J. Gange ◽  
R. D. Moore ◽  
J. E. Gallant
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Immunodeficiency Virus

scholarly journals Plasmodium falciparum Infection Does Not Affect Human Immunodeficiency Virus Viral Load in Coinfected Rwandan Adults

2014 ◽  
Vol 1 (2) ◽  
Author(s):  
Krishanthi Subramaniam ◽  
Rebeca M. Plank ◽  
Nina Lin ◽  
Adam Goldman-Yassen ◽  
Emil Ivan ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Plasmodium Falciparum ◽  
Viral Load ◽  
Malaria Infection ◽  
Hiv Transmission ◽  
Falciparum Infection ◽  
Resistance Testing ◽  
Plasmodium Falciparum Infection ◽  
Immunodeficiency Virus

Abstract Background.  Plasmodium falciparum infection has been reported to increase human immunodeficiency virus (HIV) viral load (VL), which can facilitate HIV transmission. We prospectively studied the impact of mild P falciparum coinfection on HIV VL in Rwanda. Methods.  We measured plasma HIV VL at presentation with malaria infection and weekly for 4 weeks after artemether-lumefantrine treatment in Rwandan adults infected with HIV with P falciparum malaria. Regression analyses were used to examine associations between malaria infection and HIV VL changes. Samples with detectable virus underwent genotypic drug-resistance testing. Results.  We enrolled 28 HIV-malaria coinfected patients and observed 27 of them for 5 weeks. Three patients (11%) were newly diagnosed with HIV. Acute P falciparum infection had no significant effect on HIV VL slope over 28 days of follow-up. Ten patients with VL <40 copies/mL at enrollment maintained viral suppression throughout. Seventeen patients had a detectable VL at enrollment including 9 (53%) who reported 100% adherence to ARVs; 3 of these had detectable genotypic drug resistance. Conclusions.  Unlike studies from highly malaria-endemic areas, we did not identify an effect of P falciparum infection on HIV VL; therefore, malaria is not likely to increase HIV-transmission risk in our setting. However, routine HIV testing should be offered to adults presenting with acute malaria in Rwanda. Most importantly, we identified a large percentage of patients with detectable HIV VL despite antiretroviral (ARV) therapy. Some of these patients had HIV genotypic drug resistance. Larger studies are needed to define the prevalence and factors associated with detectable HIV VL in patients prescribed ARVs in Rwanda.

Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature

2017 ◽  
Vol 29 (4) ◽  
pp. 414-417 ◽  
Author(s):  
Bo Wang ◽  
Laura Abbott ◽  
Kate Childs ◽  
Chris Taylor ◽  
Kosh Agarwal ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Case Report ◽  
Antiretroviral Therapy ◽  
Liver Injury ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Review Of Literature ◽  
Therapy Regimen ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1

A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq). The patient was not a carrier of HLA-B5701, and abacavir hypersensitivity was unlikely. We believe this is the first report of severe dolutegravir-related hepatotoxicity resulting in sub-acute liver failure and transplantation and highlights a potential need for closer monitoring after drug initiation.

Sign in / Sign up

Export Citation Format

Share Document